Amount Raised
$123 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
Description
Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced a $123 million Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest and Third Rock Ventures and new investors Agent Capital, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center (MSK), Novartis, Pavilion Capital and ShangBay Capital. In conjunction with the financing, Craig D. Gordon, M.D., Founder, Chief Executive Officer and Chief Investment Officer of GordonMD® Global Investments LP, and Irena Melnikova, Ph.D., Partner at Pfizer Ventures, have joined the Flare Therapeutics Board of Directors.
Quick answer
Flare Therapeutics raised $123 Million in a Series B round, dated March 22, 2023. Investors: Irena Melnikova, Ph.D., Partner At Pfizer Ventures, Craig D. Gordon, M.D., Founder, Chief Executive Officer And Chief Investment Officer Of Gordon Md® Global Investments Lp, Shang Bay Capital, Pavilion Capital, Novartis, Memorial Sloan Kettering Cancer Center, Eli Lilly And Company and Agent Capital. Flare Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did Flare Therapeutics raise?
- Flare Therapeutics raised $123 Million in a Series B round on March 22, 2023.
- Who invested in Flare Therapeutics?
- Irena Melnikova, Ph.D., Partner At Pfizer Ventures, Craig D. Gordon, M.D., Founder, Chief Executive Officer And Chief Investment Officer Of Gordon Md® Global Investments Lp, Shang Bay Capital, Pavilion Capital, Novartis, Memorial Sloan Kettering Cancer Center, Eli Lilly And Company and Agent Capital are named as investors in this round.
- What does Flare Therapeutics do?
- Flare Therapeutics is a biotechnology company exclusively focused on drugging transcription factors (TFs) to fully unlock the therapeutic potential of this previously elusive target class.
- Where is Flare Therapeutics based and how big is it?
- Flare Therapeutics is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Flare Therapeutics?
- Fundz holds 1 contact at Flare Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Flare Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Convergent Therapeutics raised $90M (Series A) on May 3, 2023.
- ARTHEx Biotech raised $46M (Series B) on May 3, 2023.
- Zura Bio raised $16M on May 1, 2023.
- HCW Biologics raised $26M (Debt Financing) on April 27, 2023.
- Convergent Therapeutics raised $29M on April 27, 2023.
- Radiant raised $6.3M (Seed) on April 26, 2023.
Who to call at Flare Therapeutics, and when
A new round usually means Flare Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Flare Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Flare Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Flare Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Flare Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansFlare Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.